Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 886–887 (1 August 2008) | doi:10.1038/nbt0808-886
A welcome burst of human antibodies
&
Abstract
Several recent technologies for generating human monoclonal antibodies (mAbs) have led to remarkable results in the treatment of cancer and inflammatory diseases. Meanwhile, the use of mAbs to prevent or treat infectious disease has been much more limited, with the notable exception of a mAb targeting the respiratory syncytial virus.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
